
KRAS Inhibitors Show Efficacy in Randomized NSCLC Trials
In patients with advanced KRAS G12C-mutated non–small cell lung cancer, research is shedding light on how to effectively target the driver mutation. The targeted therapies adagrasib (Krazati) and sotorasib (Lumakras) received accelerated approval and now …